NASDAQ:VTRS

Viatris (VTRS) Stock Price, News & Analysis

Viatris logo
$10.80 +0.20 (+1.89%)
Closing price 02/13/2025 04:00 PM Eastern
Extended Trading
$10.84 +0.04 (+0.37%)
As of 02/13/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Viatris Stock (NASDAQ:VTRS)

Key Stats

Today's Range
$10.58
$10.86
50-Day Range
$10.60
$12.82
52-Week Range
$9.93
$13.62
Volume
9.22 million shs
Average Volume
9.61 million shs
Market Capitalization
$12.89 billion
P/E Ratio
N/A
Dividend Yield
4.44%
Price Target
$13.67
Consensus Rating
Hold

Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
58th Percentile Overall Score

VTRS MarketRank™: 

Viatris scored higher than 58% of companies evaluated by MarketBeat, and ranked 529th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viatris has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Viatris has only been the subject of 1 research reports in the past 90 days.

  • Read more about Viatris' stock forecast and price target.
  • Earnings Growth

    Earnings for Viatris are expected to decrease by -4.10% in the coming year, from $2.68 to $2.57 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viatris is -14.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viatris is -14.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viatris has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viatris' valuation and earnings.
  • Percentage of Shares Shorted

    2.60% of the float of Viatris has been sold short.
  • Short Interest Ratio / Days to Cover

    Viatris has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viatris has recently decreased by 3.58%, indicating that investor sentiment is improving.
  • Dividend Leadership

    Viatris is a leading dividend payer. It pays a dividend yield of 4.40%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Viatris does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Viatris will have a dividend payout ratio of 18.68% next year. This indicates that Viatris will be able to sustain or increase its dividend.

  • Read more about Viatris' dividend.
  • Percentage of Shares Shorted

    2.60% of the float of Viatris has been sold short.
  • Short Interest Ratio / Days to Cover

    Viatris has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viatris has recently decreased by 3.58%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Viatris this week, compared to 3 articles on an average week.
  • Search Interest

    30 people have searched for VTRS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viatris insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Viatris is held by insiders.

  • Percentage Held by Institutions

    79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Viatris' insider trading history.
Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

VTRS Stock News Headlines

[RFK Jr CONFIRMED] But Will THIS Be His Downfall
Robert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy. Democrats smeared RFK Jr as a fraud, liar and even a murderer…. to stop him from revealing Big Pharma’s biggest secrets…
Viatris Inc. stock falls Friday, underperforms market
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. stock rises Monday, outperforms market
See More Headlines

VTRS Stock Analysis - Frequently Asked Questions

Viatris' stock was trading at $12.45 at the beginning of 2025. Since then, VTRS stock has decreased by 13.3% and is now trading at $10.80.
View the best growth stocks for 2025 here
.

Viatris Inc. (NASDAQ:VTRS) posted its quarterly earnings results on Thursday, November, 7th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.07. The firm's revenue was down 4.8% compared to the same quarter last year.
Read the conference call transcript
.

Viatris' Board of Directors approved a stock buyback program on Wednesday, February 28th 2024, which authorizes the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 6.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

Top institutional investors of Viatris include Vanguard Group Inc. (11.91%), Davis Selected Advisers (5.24%), Geode Capital Management LLC (2.52%) and Invesco Ltd. (2.46%). Insiders that own company stock include Rajiv Malik, Anthony Mauro, Paul Campbell, Harry Korman, Brian Roman, Xiangyang (Sean) Ni, Dillon Joellen Lyons, Andrew Cuneo, Der Meer Mohr Pauline Van, Menassie Taddese, Michael Goettler, Robert J Coury and W Don Cornwell.
View institutional ownership trends
.

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viatris investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Tesla (TSLA) and Walt Disney (DIS).

Company Calendar

Last Earnings
11/07/2024
Ex-Dividend for 12/13 Dividend
11/22/2024
Dividend Payable
12/13/2024
Today
2/13/2025
Next Earnings (Estimated)
2/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTRS
Employees
38,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$15.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+26.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$54.70 million
Pretax Margin
-6.32%

Debt

Sales & Book Value

Annual Sales
$15.43 billion
Cash Flow
$5.19 per share
Book Value
$17.06 per share

Miscellaneous

Outstanding Shares
1,193,590,000
Free Float
1,192,041,000
Market Cap
$12.89 billion
Optionable
Optionable
Beta
0.96
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:VTRS) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners